Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $7.2 in the prior trading day, Organon & Co (NYSE: OGN) closed at $7.06, down -1.94%. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 4.94 million shares were traded. OGN stock price reached its highest trading level at $7.21 during the session, while it also had its lowest trading level at $6.945.
Ratios:
Our goal is to gain a better understanding of OGN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.36. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.75. In the meantime, Its Debt-to-Equity ratio is 9.74 whereas as Long-Term Debt/Eq ratio is at 9.69.
JP Morgan Downgraded its Neutral to Underweight on September 06, 2024, whereas the target price for the stock was revised from $18 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 12 ’25 when COX CARRIE SMITH bought 65,400 shares for $7.67 per share. The transaction valued at 501,755 led to the insider holds 77,869 shares of the business.
COX CARRIE SMITH bought 12,469 shares of OGN for $100,591 on May 14 ’25. The Director now owns 12,469 shares after completing the transaction at $8.07 per share. On May 07 ’25, another insider, Falcione Aaron, who serves as the Chief Human Resources Officer of the company, bought 5,500 shares for $8.77 each. As a result, the insider paid 48,235 and bolstered with 62,974 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OGN now has a Market Capitalization of 1835479296 and an Enterprise Value of 9991479296. As of this moment, Organon’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.67, and their Forward P/E ratio for the next fiscal year is 1.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29 while its Price-to-Book (P/B) ratio in mrq is 2.03. Its current Enterprise Value per Revenue stands at 1.586 whereas that against EBITDA is 5.916.
Stock Price History:
The Beta on a monthly basis for OGN is 0.51, which has changed by -0.54401517 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, OGN has reached a high of $17.23, while it has fallen to a 52-week low of $6.18. The 50-Day Moving Average of the stock is -19.90%, while the 200-Day Moving Average is calculated to be -33.55%.
Shares Statistics:
The stock has traded on average 5.48M shares per day over the past 3-months and 7663950 shares per day over the last 10 days, according to various share statistics. A total of 259.98M shares are outstanding, with a floating share count of 258.95M. Insiders hold about 0.40% of the company’s shares, while institutions hold 79.11% stake in the company. Shares short for OGN as of 1761868800 were 13100266 with a Short Ratio of 2.39, compared to 1759190400 on 12815979. Therefore, it implies a Short% of Shares Outstanding of 13100266 and a Short% of Float of 6.72.
Earnings Estimates
The company has 4.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.0, with high estimates of $1.09 and low estimates of $0.91.
Analysts are recommending an EPS of between $3.84 and $3.62 for the fiscal current year, implying an average EPS of $3.76. EPS for the following year is $3.93, with 6.0 analysts recommending between $4.01 and $3.81.
Revenue Estimates
3 analysts predict $1.52B in revenue for. The current quarter. It ranges from a high estimate of $1.54B to a low estimate of $1.49B. As of. The current estimate, Organon & Co’s year-ago sales were $1.59BFor the next quarter, 3 analysts are estimating revenue of $1.52B. There is a high estimate of $1.59B for the next quarter, whereas the lowest estimate is $1.44B.
A total of 5 analysts have provided revenue estimates for OGN’s current fiscal year. The highest revenue estimate was $6.25B, while the lowest revenue estimate was $6.2B, resulting in an average revenue estimate of $6.23B. In the same quarter a year ago, actual revenue was $6.4BBased on 6 analysts’ estimates, the company’s revenue will be $6.18B in the next fiscal year. The high estimate is $6.33B and the low estimate is $5.94B.
